ASCO® 2023 Insights: "Randomized Phase 3 DeLLphi-304 Study - Tarlatamab, a DLL3-Targeting BiTE, Compared to Standard of Care in Patients With Relapsed SCLC"

120 views
July 2, 2023
0 Comments
Login to view comments. Click here to Login